

A Trial to Investigate Safety, Exposure, and Efficacy of HU6 Compared With Placebo in Adult Participants With Metabolic Dysfunction-associated Steatohepatitis (MASH)

NCT07491458

Status	RECRUITING
Phase	Phase 2
Sponsor	Rivus Pharmaceuticals, Inc.
Enrollment	180 participants

Key Eligibility Criteria

Inclusion (4)

- Male and female e30 years of age at time of signing the informed consent.
- Diagnosed with metabolic dysfunction-associated steatohepatitis (MASH)
- Women of childbearing potential must not be pregnant or breastfeeding and must use and agree to continue to use a highly effective contraceptive method throughout time on study.
- Body Mass Index (BMI) e27.0 kg/m2 to d44 kg/m2

Exclusion (16)

- Have acute or chronic hepatitis, signs, and symptoms of any other liver disease (eg, Wilson's disease) other than MASH
 - Cholecystectomy or any other surgical or medical condition or history that may potentially alter the absorption, metabolism, or excretion of study treatment.
 - History (including any family history) of malignant hyperthermia.
 - History of malignancy within 5 years (except cutaneous basal or squamous cell carcinoma, carcinoma-in-situ, or low-grade prostate cancer).
 - History of the following cardiovascular conditions within 3 months prior to randomization: acute myocardial infarction, cerebrovascular accident (stroke), unstable angina, hospitalization due to congestive heart failure (CHF), or acute CHF.
- ... and 11 more (see full listing online)

Locations (33 total)

Arizona Liver Health - Chandler, Chandler, Arizona, United States
Arizona Liver Health - Peoria, Peoria, Arizona, United States
Arizona Liver Health - Tucson, Tucson, Arizona, United States
... and 30 more locations